BACKGROUND: The fibroblast growth factor (FGF) and FGF receptor (FGFR) axis plays a critical role in tumorigenesis, but little is known of its influence in ovarian cancer. We sought to determine the association of genetic variants in the FGF pathway with risk, therapeutic response, and survival of patients with ovarian cancer. METHODS: We matched 339 non-Hispanic white ovarian cancer cases with 349 healthy controls and genotyped them for 183 single-nucleotide polymorphisms (SNPs) from 24 FGF (fibroblast growth factor) and FGFR (fibroblast growth factor receptor) genes. Genetic associations for the main effect, gene-gene interactions, and the cumulative effect were determined. RESULTS: Multiple SNPs in the FGF-FGFR axis were associated with an increased risk of ovarian cancer. In particular, FGF1 [fibroblast growth factor 1 (acidic)] SNP rs7727832 showed the most significant association with ovarian cancer (odds ratio, 2.27; 95% CI, 1.31-3.95). Ten SNPs were associated with a reduced risk of ovarian cancer. FGF18 (fibroblast growth factor 18) SNP rs3806929, FGF7 (fibroblast growth factor 7) SNP rs9920722, FGF23 (fibroblast growth factor 23) SNP rs12812339, and FGF5 (fibroblast growth factor 5) SNP rs3733336 were significantly associated with a favorable treatment response, with a reduction of risk of nonresponse of 40% to 60%. Eleven SNPs were significantly associated with overall survival. Of these SNPs, FGF23 rs7961824 was the most significantly associated with improved prognosis (hazard ratio, 0.55; 95% CI, 0.39-0.78) and was associated with significantly longer survival durations, compared with individuals with the common genotype at this locus (58.1 months vs. 38.0 months, P = 0.005). Survival tree analysis revealed FGF2 rs167428 as the primary factor contributing to overall survival. CONCLUSIONS: Significant associations of genetic variants in the FGF pathway were associated with ovarian cancer risk, therapeutic response, and survival. The discovery of multiple SNPs in the FGF-FGFR pathway provides a molecular approach for risk assessment, monitoring therapeutic response, and prognosis.
BACKGROUND: The fibroblast growth factor (FGF) and FGF receptor (FGFR) axis plays a critical role in tumorigenesis, but little is known of its influence in ovarian cancer. We sought to determine the association of genetic variants in the FGF pathway with risk, therapeutic response, and survival of patients with ovarian cancer. METHODS: We matched 339 non-Hispanic white ovarian cancer cases with 349 healthy controls and genotyped them for 183 single-nucleotide polymorphisms (SNPs) from 24 FGF (fibroblast growth factor) and FGFR (fibroblast growth factor receptor) genes. Genetic associations for the main effect, gene-gene interactions, and the cumulative effect were determined. RESULTS: Multiple SNPs in the FGF-FGFR axis were associated with an increased risk of ovarian cancer. In particular, FGF1 [fibroblast growth factor 1 (acidic)] SNP rs7727832 showed the most significant association with ovarian cancer (odds ratio, 2.27; 95% CI, 1.31-3.95). Ten SNPs were associated with a reduced risk of ovarian cancer. FGF18 (fibroblast growth factor 18) SNP rs3806929, FGF7 (fibroblast growth factor 7) SNP rs9920722, FGF23 (fibroblast growth factor 23) SNP rs12812339, and FGF5 (fibroblast growth factor 5) SNP rs3733336 were significantly associated with a favorable treatment response, with a reduction of risk of nonresponse of 40% to 60%. Eleven SNPs were significantly associated with overall survival. Of these SNPs, FGF23rs7961824 was the most significantly associated with improved prognosis (hazard ratio, 0.55; 95% CI, 0.39-0.78) and was associated with significantly longer survival durations, compared with individuals with the common genotype at this locus (58.1 months vs. 38.0 months, P = 0.005). Survival tree analysis revealed FGF2rs167428 as the primary factor contributing to overall survival. CONCLUSIONS: Significant associations of genetic variants in the FGF pathway were associated with ovarian cancer risk, therapeutic response, and survival. The discovery of multiple SNPs in the FGF-FGFR pathway provides a molecular approach for risk assessment, monitoring therapeutic response, and prognosis.
Authors: Laura-Mae Baldwin; Katrina F Trivers; Barbara Matthews; C Holly A Andrilla; Jacqueline W Miller; Donna L Berry; Denise M Lishner; Barbara A Goff Journal: Ann Intern Med Date: 2012-02-07 Impact factor: 25.391
Authors: Dong Liang; Larissa Meyer; David W Chang; Jie Lin; Xia Pu; Yuanqing Ye; Jian Gu; Xifeng Wu; Karen Lu Journal: Cancer Res Date: 2010-11-30 Impact factor: 12.701
Authors: Kelly L Bolton; Jonathan Tyrer; Honglin Song; Susan J Ramus; Maria Notaridou; Chris Jones; Tanya Sher; Aleksandra Gentry-Maharaj; Eva Wozniak; Ya-Yu Tsai; Joanne Weidhaas; Daniel Paik; David J Van Den Berg; Daniel O Stram; Celeste Leigh Pearce; Anna H Wu; Wendy Brewster; Hoda Anton-Culver; Argyrios Ziogas; Steven A Narod; Douglas A Levine; Stanley B Kaye; Robert Brown; Jim Paul; James Flanagan; Weiva Sieh; Valerie McGuire; Alice S Whittemore; Ian Campbell; Martin E Gore; Jolanta Lissowska; Hanna P Yang; Krzysztof Medrek; Jacek Gronwald; Jan Lubinski; Anna Jakubowska; Nhu D Le; Linda S Cook; Linda E Kelemen; Angela Brooks-Wilson; Angela Brook-Wilson; Leon F A G Massuger; Lambertus A Kiemeney; Katja K H Aben; Anne M van Altena; Richard Houlston; Ian Tomlinson; Rachel T Palmieri; Patricia G Moorman; Joellen Schildkraut; Edwin S Iversen; Catherine Phelan; Robert A Vierkant; Julie M Cunningham; Ellen L Goode; Brooke L Fridley; Susan Kruger-Kjaer; Jan Blaeker; Estrid Hogdall; Claus Hogdall; Jenny Gross; Beth Y Karlan; Roberta B Ness; Robert P Edwards; Kunle Odunsi; Kirsten B Moyisch; Julie A Baker; Francesmary Modugno; Tuomas Heikkinenen; Ralf Butzow; Heli Nevanlinna; Arto Leminen; Natalia Bogdanova; Natalia Antonenkova; Thilo Doerk; Peter Hillemanns; Matthias Dürst; Ingo Runnebaum; Pamela J Thompson; Michael E Carney; Marc T Goodman; Galina Lurie; Shan Wang-Gohrke; Rebecca Hein; Jenny Chang-Claude; Mary Anne Rossing; Kara L Cushing-Haugen; Jennifer Doherty; Chu Chen; Thorunn Rafnar; Soren Besenbacher; Patrick Sulem; Kari Stefansson; Michael J Birrer; Kathryn L Terry; Dena Hernandez; Daniel W Cramer; Ignace Vergote; Frederic Amant; Diether Lambrechts; Evelyn Despierre; Peter A Fasching; Matthias W Beckmann; Falk C Thiel; Arif B Ekici; Xiaoqing Chen; Sharon E Johnatty; Penelope M Webb; Jonathan Beesley; Stephen Chanock; Montserrat Garcia-Closas; Tom Sellers; Douglas F Easton; Andrew Berchuck; Georgia Chenevix-Trench; Paul D P Pharoah; Simon A Gayther Journal: Nat Genet Date: 2010-09-19 Impact factor: 41.307
Authors: Jikai Yin; Karen Lu; Jie Lin; Lei Wu; Michelle A T Hildebrandt; David W Chang; Larissa Meyer; Xifeng Wu; Dong Liang Journal: PLoS One Date: 2011-09-30 Impact factor: 3.240
Authors: Barbara E Stranger; Stephen B Montgomery; Antigone S Dimas; Leopold Parts; Oliver Stegle; Catherine E Ingle; Magda Sekowska; George Davey Smith; David Evans; Maria Gutierrez-Arcelus; Alkes Price; Towfique Raj; James Nisbett; Alexandra C Nica; Claude Beazley; Richard Durbin; Panos Deloukas; Emmanouil T Dermitzakis Journal: PLoS Genet Date: 2012-04-19 Impact factor: 5.917
Authors: Muktar Ahmed; Ville-Petteri Mäkinen; Anwar Mulugeta; Jisu Shin; Terry Boyle; Elina Hyppönen; Sang Hong Lee Journal: Commun Biol Date: 2022-06-21
Authors: M L King; M E Lindberg; G R Stodden; H Okuda; S D Ebers; A Johnson; A Montag; E Lengyel; J A MacLean Ii; K Hayashi Journal: Oncogene Date: 2014-09-01 Impact factor: 9.867